| Literature DB >> 29042997 |
Min Yang1, Changji Du2, Yinping Wang2, Jun Liu1.
Abstract
Hashimoto's thyroiditis (HT) is typically associated with insulin resistance. The aim of the present study was to investigate the role of regulatory B cells (Bregs) in insulin resistance in patients with HT. A total of 52 female patients with type I HT and 35 matched healthy volunteers were enrolled. Demographic and laboratorial data were collected. A 75 g oral glucose tolerance test was performed on each subject. Flow cytometry was performed to evaluate the levels of CD19+CD24hiCD38hi Bregs in peripheral blood. Patients with HT exhibited significantly higher postprandial insulin levels (P<0.01), but normal glucose levels. The level of CD19+CD24hiCD38hi Bregs in patients with HT decreased significantly (P=0.0002) compared with the controls. Pearson's linear correlation model revealed a significant, negative association between anti-thyroid peroxidase antibodies (TPOAb) and homeostasis model assessment of β cell (r=-0.313, P=0.014). The same correlation model revealed a significant, negative association between TPOAb and the disposition index (DI; r=-0.305, P=0.017), and between anti-thyroglobulin antibodies and DI (r=-0.321, P=0.013). Patients with a decreased ratio of CD19+CD24hiCD38hi Bregs to CD19+ lymphocytes exhibited higher levels of total cholesterol and low-density lipoprotein cholesterol. A decrease in the ratio of CD19+CD24hiCD38hi Bregs to lymphocytes was a significant independent risk factor for hyperinsulinemia (odds ratio=1.372, P=0.035). A decrease in peripheral blood CD19+CD24hiCD38hi Bregs is associated with insulin resistance in HT patients, and was an independent risk factor for postprandial hyperinsulinemia. The present study provided a novel insight into the development of effective therapeutic strategies targeting immune mechanisms associated with HT.Entities:
Keywords: Hashimoto's thyroiditis; insulin resistance; islet function; regulatory B cell
Year: 2017 PMID: 29042997 PMCID: PMC5639318 DOI: 10.3892/etm.2017.4925
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447